The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Invivyd, Inc. Announces Departure of CEO David Hering and Appointment of Interim CEO Jeremy Gowler
PUBLIC · IVVDApr 12, 2024•about 2 years ago
Position
Chief Executive Officer
Company
Invivyd
Jeremy Gowler
WalthamBiotechnology
Description
Invivyd, Inc. has announced the departure of Chief Executive Officer and Director David Hering, effective April 11, 2024, and the appointment of Jeremy Gowler as the Interim CEO, retaining his roles as COO and CCO.
Company Information
Company
Invivyd
Location
1601 Trapelo Road
Waltham, Massachusetts, United States
About
Invivyd, Inc. (Nasdaq: IVVD) is a commercial-stage company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
WalthamBiotechnology